Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.48 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31391124 | 1.00 | ALDH1A1 (0.51) | ALDH1A1HTTXBP1TAS1R3TAS1R1 | |
| SCHEMBL2994523 | 1.00 | ALDH1A1 (0.51) | ALDH1A1HTTXBP1TAS1R3TAS1R1 | |
| SCHEMBL13240611 | 1.00 | ALDH1A1 (0.51) | ALDH1A1HTTXBP1TAS1R3TAS1R1 | |
| Toluene SCHEMBL29131456 | 0.91 | LMNA (0.48) | ALDH1A1HTTXBP1TAS1R3TAS1R1 | |
| SCHEMBL7213715 | 0.89 | PIN1 (0.58) | ALDH1A1HTTXBP1TAS1R3TAS1R1 | |
| SCHEMBL30070890 | 0.89 | PIN1 (0.58) | ALDH1A1HTTXBP1TAS1R3TAS1R1 | |
| SCHEMBL27261538 | 0.85 | HTT (0.51) | ALDH1A1HTTXBP1PIN1BLM | |
| SCHEMBL2796237 | 0.84 | HTT (0.54) | ALDH1A1HTTPIN1BLMMEN1 | |
| SCHEMBL2792830 | 0.84 | HTT (0.54) | ALDH1A1HTTPIN1BLMMEN1 | |
| SCHEMBL242244 | 0.84 | HTT (0.54) | ALDH1A1HTTPIN1BLMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117263932-A | Method for reducing residual solvent in palonosetron hydrochloride | 药源药物化学（上海）有限公司 | 2023-12-22 | — | — | CN | claimed |
| CN-117263931-A | Method for preparing palonosetron hydrochloride | 药源药物化学（上海）有限公司 | 2023-12-22 | — | — | CN | claimed |
| CN-108178756-B | Preparation method of palonosetron hydrochloride and intermediate thereof | 上海博志研新药物技术有限公司 | 2020-03-27 | — | — | CN | claimed |
| CN-117263931-A | Method for preparing palonosetron hydrochloride | 药源药物化学（上海）有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-117263932-A | Method for reducing residual solvent in palonosetron hydrochloride | 药源药物化学（上海）有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-117263931-A | Method for preparing palonosetron hydrochloride | 药源药物化学（上海）有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-108178756-B | Preparation method of palonosetron hydrochloride and intermediate thereof | 上海博志研新药物技术有限公司 | 2020-03-27 | — | — | CN | disclosed |
| US-20130079521-A1 | NOVEL PALONOSETRON SALTS AND PROCESSES FOR PREPARATION AND PURIFICATION THEREOF | CHEMAGIS LTD. (IL) | 2013-03-28 | — | — | US | disclosed |
| US-8334388-B2 | Palonosetron salts and processes for preparation and purification thereof | CHEMAGIS LTD. (IL) | 2012-12-18 | — | — | US | disclosed |
| US-20100174080-A1 | NOVEL PALONOSETRON SALTS AND PROCESSES FOR PREPARATION AND PURIFICATION THEREOF | CHEMAGIS LTD. (IL) | 2010-07-08 | — | — | US | disclosed |
| EP-2155199-A2 | NOVEL PALONOSETRON SALTS AND PROCESSES FOR PREPARATION AND PURIFICATION THEREOF | Chemagis Ltd. (IL) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008146283-A2 | NOVEL PALONOSETRON SALTS AND PROCESSES FOR PREPARATION AND PURIFICATION THEREOF | CHEMAGIS LTD. (IL) | 2008-12-04 | — | — | WO | disclosed |
| US-5576434-A | (1-azabicyclo[2.2.2]oct-3-yl) (1,2,3,4-tetrahydronaphthalen-1-ylmethyl)amine and n-(1-azabicyclo[2.2.2]oc | HELSINN HEALTHCARE SA (CH) | 1996-11-19 | — | — | US | disclosed |
| US-5510486-A | Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one | SYNTEX (U.S.A.) INC. (US) | 1996-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100174080-A1 | NOVEL PALONOSETRON SALTS AND PROCESSES FOR PREPARATION AND PURIFICATION THEREOF | HTR3C, HTR3A, CYP3A43 | ALDH1A1 2996/4885HTT 2163/4885XBP1 4369/4885 |
| US-20130079521-A1 | NOVEL PALONOSETRON SALTS AND PROCESSES FOR PREPARATION AND PURIFICATION THEREOF | HTR3C, HTR3A, CYP3A43 | ALDH1A1 2845/4885HTT 2274/4885XBP1 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.